HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• ‘Under-appreciation’ for anemia in elderly hinders research, treatment
• Ovarian suppression plus tamoxifen reduced breast cancer recurrence in high-risk young women
• Robust data needed to settle maintenance therapy debate in hematologic malignancies John Sweetenham, MD, FRCP, FACP
• FDA approves Blincyto for PH-negative precursor B-cell ALL
• FDA approves Jakafi for polycythemia vera
• High-dose chemotherapy failed to extend PFS in germ cell tumors
• Primary tumor site affected clinical features, outcomes in pediatric neuroblastoma
• Lung cancer clinical trials routinely exclude cancer survivors
• S-1 plus oxiliplatin may be new first-line standard for advanced gastric cancer
• Association presents award for research
• Investigator receives NCI leadership award
• Lurie Cancer Center appoints director
• Ohio State makes staff announcements
• Palliative medicine director honored
• Professor receives Florence Prize
• Weekly paclitaxel or docetaxel every 3 weeks extended DFS in breast cancer
• Nilotinib with low-intensity chemotherapy may be viable in older patients with Ph+ALL
• AG-221 may be safe, tolerable for patients with AML
• ASTRO presentations highlight advances in glioma, prostate cancer, NSCLC Walter J. Curran Jr., MD
• CATCH: Tinzaparin reduced recurrent VTE in patients with active cancer
• KEYNOTE-013: Pembrolizumab active, safe in pre-treated Hodgkin’s lymphoma
• Reduced dietary fat intake extended survival in some women with breast cancer
• Sorafenib extended EFS in AML
• Untreated emboli may increase risk for recurrent venous thromboembolism
• Six chemotherapy cycles failed to improve outcomes in node-negative breast cancer
• Ovarian suppression plus tamoxifen reduced breast cancer recurrence in high-risk premenopausal women
• Tamoxifen conferred long-term breast cancer prevention benefit